Retatrutide Dosage: What Trials Actually Used (There's No Approved Dose)

Search "retatrutide dosage" and you'll find dosage calculators, dosing charts, and confident weekly schedules presented as settled fact. None of it is an approved dose, because there is no approved retatrutide product. What exists instead is trial data — real, published, randomized human dosing data, which is more than can be said for most research-chemical peptides — but trial data collected under medical supervision, with lab monitoring and a structured titration protocol, is not the same thing as a consumer dosing chart. This article lays out exactly what the trials used and why that gap matters.

For the safety side of this molecule — including a new adverse-event signal that only appeared once dosing moved into Phase 3 — see our companion article on retatrutide side effects. For the efficacy and body-composition picture, see retatrutide for athletes and body recomposition.

The Only Real Human Dosing Data: The Phase 2 Trial

The most detailed published human dosing data for retatrutide comes from its 48-week, randomized, double-blind, placebo-controlled Phase 2 obesity trial in 338 adults¹. The trial tested weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, and 12 mg, reaching those maintenance doses through a structured titration schedule rather than starting participants at the target dose on day one¹. Two different starting-dose strategies were compared for the higher maintenance doses: beginning at 2 mg versus beginning at 4 mg before stepping up. The trial found that the slower 2 mg starting dose reduced gastrointestinal side effects during escalation while reaching the same eventual maintenance dose and comparable weight-loss outcomes¹ — a finding that only exists because the trial had a protocol and clinical monitoring to test it against.

At 48 weeks, weight loss tracked dose closely: −8.7% at 1 mg, −17.1% at 4 mg (pooled), −22.8% at 8 mg (pooled), and −24.2% at 12 mg, versus −2.1% on placebo¹. That dose-response relationship is real and well-documented — but notice what it does not tell you: it does not tell you what dose is safe to self-titrate without lab work, it does not tell you how to adjust for body weight (the trial dosed by fixed milligram amount, not mg/kg), and it does not establish a ceiling beyond 12 mg, because 12 mg was simply the highest dose the trial tested, not necessarily the highest tolerable one.

Phase 3: The Doses Actually Headed Toward Approval

Eli Lilly's Phase 3 TRIUMPH program has continued dose-finding at the higher end. The TRIUMPH-4 trial, testing knee osteoarthritis and obesity, evaluated the two highest investigational doses — 9 mg and 12 mg — over 68 weeks, with topline results disclosed in December 2025 showing up to 28.7% mean weight loss at 68 weeks on the 12 mg dose². Lilly has also stated that the broader TRIUMPH program includes a lower 4 mg maintenance dose in addition to 9 mg and 12 mg, with further results expected through 2026²³. The doses being carried into the eventual FDA filing are therefore not identical to the exact regimen tested in the original 2023 Phase 2 paper — dose selection has continued to evolve across the trial program, which is normal drug development and another reason a "final" consumer dosing chart circulating online cannot actually be final.

Why There Is No Legitimate Consumer Dose

Put the two sections above together and the honest conclusion is unavoidable: every retatrutide dose that has ever produced a measured, published human result was administered inside a clinical trial, with medical screening, lab monitoring, and a fixed manufacturing source under GMP conditions. None of that infrastructure exists for a vial purchased online. Three specific gaps matter:

No body-weight adjustment. The trials dosed by fixed milligram amount (1, 4, 8, 9, or 12 mg), not by body weight — so there is no validated formula for scaling a dose to an individual's size the way some other drugs allow.

No verified vial contents. Retatrutide sold outside a trial is unregulated research-market material. Its labeled concentration is unverifiable without independent testing — a general problem across this category that we cover in how to verify a peptide's COA and third-party testing and peptide vendor red flags. A miscalibrated vial makes any "dose" arithmetic meaningless regardless of how precisely it's calculated.

No titration supervision. The trial's own finding — that a slower starting dose reduced GI side effects — only became known because researchers were tracking it. Self-titrating without that structure means repeating the trial's early, harder-tolerated approach with none of the monitoring that made it safe to observe.

None of this is a reason to distrust the trial data itself, which is genuinely strong. It's a reason to distinguish "retatrutide has real published dosing data" (true) from "there is a safe, established dose for personal use" (false, because no regulator has reviewed a safety and efficacy package sufficient to set one).

Where This Leaves the "Retatrutide Dosage Calculator" Searches

The high search volume around retatrutide dosage charts and calculators reflects real, legitimate curiosity about a molecule with genuinely impressive trial results — not a red flag by itself. But a calculator that converts a vial's milligram content into microliters per injection is solving a reconstitution arithmetic problem, not a medical dosing problem. It can tell you precisely how much liquid corresponds to a given number of milligrams, assuming the vial's labeled content is accurate and assuming you already know what dose you're trying to hit — neither of which retatrutide's current unapproved status can guarantee. Precision in the arithmetic is not the same as evidence for the number fed into it, a pattern we've documented across multiple research peptides, most explicitly in our BPC-157 dosage review.

Bottom Line

Retatrutide has more real human dosing data behind it than almost any other compound covered on this site — a full Phase 2 dose-response curve across four doses, plus Phase 3 trials refining the top end toward 9 and 12 mg. But every one of those doses was administered inside a monitored clinical trial, using a manufactured, verified drug supply, with a titration protocol designed specifically to manage the tolerability the trial found. As of this writing retatrutide remains unapproved by the FDA, with Eli Lilly targeting a Biologics License Application submission no earlier than Q1 2027⁴. Until that changes, "what dose did the trials use" and "what dose should a person use" remain two different questions, and only the first one has a real answer.